Antimicrobial ReportsStrategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant OrganismsDonà, Daniele MD, PhD*,†; Sharland, Mike MD*; Heath, Paul T. MD*; Folgori, Laura MD*,‡Author Information From the *Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George’s University of London, London, United Kingdom †Division of Paediatric Infectious Diseases, Department for Woman and Child Health, University of Padua, Padua ‡Paediatric Infectious Disease Unit, Department of Paediatrics, Luigi Sacco Hospital, University of Milan, Milan, Italy. Accepted for publication April 19, 2019. The authors have no funding or conflicts of interest to disclose. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com). Address for correspondence: Laura Folgori, MD, St George’s University of London, Jenner Wing, Level 2, Room 2.215E, Cranmer Terrace, London SW17 0RE, United Kingdom. E-mail: [email protected]. The Pediatric Infectious Disease Journal: August 2019 - Volume 38 - Issue 8 - p 825-827 doi: 10.1097/INF.0000000000002381 Buy SDC Metrics Abstract The optimal standard of care for carbapenem-resistant bloodstream infections in children is currently unknown. This systematic review, aiming to define the best available treatments to be compared with new antibiotics in clinical trials, clearly points out the paucity of available data. The simplification and a wider harmonization of study design are a global priority to inform the best strategies to treat these life-threatening infections in children. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.